Stock Commentary - Europe - week to April 17, 2006
23 April 2006
EUROPEAN: bourses were all down significantly, falling sharply on the first reporting day, April 11, after the Italian election fiasco which pointed to political paralysis. This was followed by worries about high commodity prices in the Easter holiday shortened week to April 17. FRANKFURT's Xetra Dax fell 1.4%, hit by profit-taking since April 6, after the index made strong gains prior to that. Here, Schwarz Pharma was the highlight, rising 9.6%, on news of its out-licensing deal with US drugs giant Pfizer for fesoterodine, which includes an upfront payment of $100.0 million plus developmental and regulatory milestones, as well as royalties which could add up to a further $110.0 million. LION Biosciences drifted back 3%, after leaping more than 29% the previous week. PARIS's CAC 40 plunged 3.4% on the week, with bioMerieux down 2.7%, after the company said it expected to raise some $1.22-$1.83 billion to finance acquisitions (see page 2). ZURICH saw a poor performance from the drug sector, with only Roche managing a small, 0.7% rise, while Novartis fell 2.3% and Serono was down 3%, still suffering from the news that it had pulled out of any takeover talks (Marketletter April 17).
LONDON: share prices were virtually unchanged over the three-day trading week, with the FTSE 100 having notched up a five-year high on April 11. There was little news in the pharmaceutical sector and stocks tracked moved in a narrow range, with the best being a 3.2% rise for XTL Bio and worst a 3.9% decline for Acambis. Drub majors AstraZeneca and GlaxoSmithKline managed rises of 0.6% and 0.3%, respectively. Skyepharma went into reverse with a 3.8% fall.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
An ophthalmic gene therapy company aiming to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
Stock Commentary - Europe - week to April 17, 2006
EUROPEAN: bourses were all down significantly, falling sharply on the first reporting day, April 11, after the Italian election fiasco which pointed to political paralysis. This was followed by worries about high commodity prices in the Easter holiday shortened week to April 17. FRANKFURT's Xetra Dax fell 1.4%, hit by profit-taking since April 6, after the index made strong gains prior to that. Here, Schwarz Pharma was the highlight, rising 9.6%, on news of its out-licensing deal with US drugs giant Pfizer for fesoterodine, which includes an upfront payment of $100.0 million plus developmental and regulatory milestones, as well as royalties which could add up to a further $110.0 million. LION Biosciences drifted back 3%, after leaping more than 29% the previous week. PARIS's CAC 40 plunged 3.4% on the week, with bioMerieux down 2.7%, after the company said it expected to raise some $1.22-$1.83 billion to finance acquisitions (see page 2). ZURICH saw a poor performance from the drug sector, with only Roche managing a small, 0.7% rise, while Novartis fell 2.3% and Serono was down 3%, still suffering from the news that it had pulled out of any takeover talks (Marketletter April 17).
LONDON: share prices were virtually unchanged over the three-day trading week, with the FTSE 100 having notched up a five-year high on April 11. There was little news in the pharmaceutical sector and stocks tracked moved in a narrow range, with the best being a 3.2% rise for XTL Bio and worst a 3.9% decline for Acambis. Drub majors AstraZeneca and GlaxoSmithKline managed rises of 0.6% and 0.3%, respectively. Skyepharma went into reverse with a 3.8% fall.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
Become a subscriber
£820
Or £77 per month
Chairman, Sanofi Aventis UK
Companies featured in this story
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze